The Effect of Caffeine on Ischemic Preconditioning
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00184912|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : November 29, 2006
Ischaemic preconditioning (IP) describes the phenomenon that brief periods of ischaemia render the (myocardial) muscle more resistant to a subsequent more prolonged period of ischaemia and reperfusion. Animal studies have provided evidence that adenosine receptor stimulation is an important mediator of IP. As caffeine is an effective adenosine receptor antagonist already at concentrations reached after regular coffee consumption, we aimed to assess whether caffeine impairs IP in humans in vivo. We used a novel and well-validated model to study IP in humans: 99m-Tc-annexin A5 scintigraphy in forearm skeletal muscle.
24 healthy volunteers were randomly assigned to either caffeine (4 mg/kg/iv in 10 minutes) or saline before a protocol for IP.
|Condition or disease||Intervention/treatment||Phase|
|Caffeine Ischemic Preconditioning Ischemia-Reperfusion Injury||Drug: caffeine Drug: Technetium-TC99m-labeled Annexin A5 Procedure: ten minutes forearm ischemia Procedure: ischemic forearm exercise||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Caffeine Reduces Acute Ischemic Preconditioning|
|Study Start Date :||September 2003|
|Study Completion Date :||January 2006|
- Percentual difference in Annexin A5 targetting between the experimental and control arm one and four hours after intravenous injection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184912
|Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology|
|Nijmegen, Gelderland, Netherlands, 6500 HB|
|Principal Investigator:||Gerard Rongen, MD, Phd||Radboud University Nijmegen Medical Centre / Department of pharmacology and Toxicology|